Videos

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

FEATURING:

Dr David Spigel

July 25, 2018

ASCO 2018 Insights, Immunotherapy, Personalized Medicine

How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients

How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients

FEATURING:

Dr David Spigel

July 25, 2018

ASCO 2018 Insights

The Most Important Advances in Precision Medicine Presented at ASCO 2018

The Most Important Advances in Precision Medicine Presented at ASCO 2018

FEATURING:

Dr David Spigel

July 25, 2018

ASCO 2018 Insights

Patient-Centric Care Is Changing How Patients with Cancer Are Treated

Patient-Centric Care Is Changing How Patients with Cancer Are Treated

FEATURING:

Dr David Spigel

July 25, 2018

ASCO 2018 Insights

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

FEATURING:

Dr David Spigel

July 25, 2018

ASCO 2018 Insights

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

FEATURING:

Dr Matthew Goetz

January 10, 2018

Breast Cancer, SABCS Highlights

Questions About Treating Patients Using a CDK4/6 Inhibitor

Questions About Treating Patients Using a CDK4/6 Inhibitor

FEATURING:

Dr Matthew Goetz

January 10, 2018

Breast Cancer, SABCS Highlights

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?

FEATURING:

Dr Matthew Goetz

January 10, 2018

Breast Cancer, SABCS Highlights

The Use of Chemotherapy in the Metastatic Setting

The Use of Chemotherapy in the Metastatic Setting

FEATURING:

Dr Matthew Goetz

January 10, 2018

Breast Cancer, SABCS Highlights

The Mechanism of Action of CDK4/6 Inhibitors

The Mechanism of Action of CDK4/6 Inhibitors

FEATURING:

Dr Matthew Goetz

January 10, 2018

Breast Cancer, SABCS Highlights

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

FEATURING:

January 10, 2018

Breast Cancer, SABCS Highlights

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

FEATURING:

January 10, 2018

Breast Cancer, SABCS Highlights

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

FEATURING:

January 10, 2018

Breast Cancer, SABCS Highlights

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

FEATURING:

January 10, 2018

Breast Cancer, SABCS Highlights

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

FEATURING:

January 10, 2018

Breast Cancer, SABCS Highlights

Page 8 of 14

5
6
7
8
9
10
11